EKF Diagnostics Holdings PLC Trading update (1951N)
January 16 2019 - 1:00AM
UK Regulatory
TIDMEKF
RNS Number : 1951N
EKF Diagnostics Holdings PLC
16 January 2019
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
EKF Diagnostics Holdings plc
("EKF", the "Company")
Trading update
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed
point-of-care business, provides the following trading update.
The Company announces that adjusted EBITDA(1) for the year ended
31 December 2018 is expected to be comfortably ahead of market
expectations which had been upgraded during the period. In
addition, cash generation in the second half has been very strong
with net cash at the end of the year of GBP9.4m (31 December 2017:
GBP7.0m net cash), which is after a GBP3.1m investment in Renalytix
AI PLC and share buybacks of almost GBP0.9m.
In 2018 EKF continued to make significant headway in delivering
on its strategy. The outlook for the Company in 2019 is positive as
it looks to benefit from the groundwork laid in 2018, including a
full-year contribution from the OEM contract with McKesson-Surgical
Inc. for the distribution of Diaspect Tm in the US and the enzyme
business with Oragenics, Inc.
(1) Earnings before interest, tax, depreciation and
amortisation, excluding exceptional items and share based
payments.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman Tel: 029 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nomad & Broker) Tel: 020 7496 3000
Aubrey Powell / Lauren Kettle / George Tzimas
(Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus/ Lianne Cawthorne Mob: 07980 541 893 / 07584
391 303
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analyzers in regular use
across more than 100 countries. EKF specializes in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analyzers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TSTLFFLLLTIELIA
(END) Dow Jones Newswires
January 16, 2019 02:00 ET (07:00 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2024 to May 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From May 2023 to May 2024